Clinical Trial Update: Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a fixed-dose combination of estradiol 0.5 mg and dydrogesterone 2.5 mg for vasomotor symptoms in postmenopausal women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopause

Drugs mentioned

• Dydrogesterone (dydrogesterone)
• ESTRADIOL (Estradiol)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Postmenopause | Phase 3 | Status: COMPLETED